Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/70—Sulfur atoms
  • C07D213/71—Sulfur atoms to which a second hetero atom is attached
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

• This invention relates to new compounds, in particular pyridinyl sulfonamide derivatives, to processes for preparing such compounds, to their use as inhibitors of AOC3, to methods for their therapeutic use, in particular in diseases and conditions mediated by the inhibition of AOC3, and to pharmaceutical compositions comprising them.
• AOC3 amine oxidase, copper containing 3; vascular adhesion protein 1
• AOC3 has two closely homologous genes in the human genome: AOC1 which corresponds to a diamine oxidase (Chassande, O. et al., 1994, J. Biol. Chem.
• AOC4 is a sequence that does not lead to a functional gene product in humans due to an internal stop-codon (Schwelberger, H. G., 2007, J. Neural Transm. 114: 757-762).
• the enzyme contains an oxidized 2,4,5-trihydroxy-phenylalaninequinone (TPQ) and a copper ion in the active side.
• This characteristic catalytic center classifies the semi- carbazide-sensitive amine oxidase (SSAO, copper-containing amine:oxygen oxido- reductase (deaminating)):
• SSAO semi- carbazide-sensitive amine oxidase
• the type II membrane protein belongs to the family of copper containing amine oxidases together with several other diamine and the lysyl oxidases.
• the later enzymes can be distinguished from AOC3 in their preference for diamines and the low sensitivity towards semicarbazide inhibition (Dunkel, P. et al., 2008, Curr. Med. Chem. 15: 1827-1839).
• monoamine oxidases contain the flavin adenine dinucleotide (FAD) cofactor in their reactive center like monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO- B) and follow therefore a different reaction scheme.
• FAD flavin adenine dinucleotide
• AOC3 catalyzes a two-step reaction mechanism for the oxidative deamination of primary aliphatic and aromatic amines.
• the primary amine forms a Schiff-base with a TPQ carbonyl group.
• hydrolysis takes place and an aldehyde and the aminoquinol form of TPQ are formed in the active site.
• the aminoquinol form of TPQ is oxidized and hydrolyzed to re-generate TPQ under the formation of ammonia and peroxide with the help of the copper ion (Mure, M. et al., 2002, Biochemistry 41 : 9269-9278).
• the byproduct hydrogen peroxide is sensed by the tissue as a messenger of inflammation.
• This reaction product is able to activate the endothelium and is fostering the activation of leukocytes.
• Siglec-10 as a membrane bound substrate provides a mechanistic understanding of how the enzymatic reaction could trigger the leukocyte transmigration through activated endothelia.
• the binding of Siglec-10 to AOC3 was shown in several adhesion assays and led to increased hydrogen peroxide production (Kivi, E. et al., 2009, Blood 1 14: 5385-5392). Binding of activated leukocytes to the dimeric, extracellular AOC3 via the Siglec-10 generates a transient association to the activated endothelium. Therefore, the rolling velocity of leukocytes is reduced, which increases the transmigration of leukocytes into the interstitium of inflamed tissues.
• AOC3 activity can be found in most tissues and is mainly expressed in endothelial cells, smooth muscle cells and adipocytes (Boomsma, F. et al.,2000, Comp Biochem. Physiol C. Toxicol. Pharmacol. 126: 69-78; O'Sullivan, J. et al.,2004, Neurotoxicology 25: 303-315).
• AOC3 activity is constitutive in the liver sinusoideal endothelial cells (McNab, G. et al., 1996, Gastroenterology 1 10: 522-528) and mRNA expression is further upregulated under inflammatory conditions in this tissue (Lalor, P. F. et al., 2002, Immunol.
• AOC3 not only exists as a membrane protein, but can also be found as soluble plasma activity probably due to a metalloprotease mediated shedding process (Abella, A. et al., 2004, Diabetologia 47: 429-438); Boomsma, F. et al., 2005, Diabetologia 48: 1002-1007; Stolen, C. M. et al., 2004, Circ. Res. 95: 50- 57)). Elevated levels of soluble AOC3 have been observed in diabetes (Li, H. Y. et al., 2009, Clin. Chim.
• AOC3 The role of AOC3 in the activation of inflammation via peroxide generation and the recruitment of leukocytes to activated endothelium makes it an attractive target for the treatment of inflammatory components in several diseases. Therefore, a variety of small molecular compounds and antibodies have been tested in different disease animal models. Amongst those, the inhibition of AOC3 showed beneficial effects in the models of melanoma and lymphoma cancer (Marttila-lchihara, F. et al., 2010, J. Immunol. 184: 3164-3173), acute and chronic joint (Tabi, T. et al., 2013, J. Neural Transm. 120: 963-967) or lung (Foot, J. S. et al., 2013, J. Pharmacol.
• the amine oxidase copper containing 2 (AOC2) enzyme is a family member of homodimeric amine oxidases sensitive to the inhibition of semicarbazide.
• the human enzyme shares 65% of its amino acids with the closest homolog AOC3 (Zhang et al., 2003, Gene 318: 45-53).
• Recombinant overexpression of the longer version sv1 provides evidence of cell surface expression and enzymatic activity, whereas the shorter version sv2 remains cytoplasmatic in a FIEK293 in vitro expression system.
• AOC2 and AOC3 exhibit different substrate profiles due to structural differences in the active sites: AOC2 exerts a high prevalence for 2-phenylethylamine and tryptamine and a low activity on the turnover of methylamine or benzylamine compared to AOC3 enzymatic activity. Nevertheless, both enzymes can form heterodimers that reconstitute enzymatic active centers with retained substrate selectivity.
• Expression analysis of AOC2 mRNA shows a broad expression of the two splice variants sv1 and sv2 of the AOC2 gene in lung, brain, heart, liver, kidney, pancreas and peripheral blood lymphocytes (Kaitaniemi et al., 2009, Cellular and Molecular Life 66: 2743-2757).
• AOC2 enzymatic tissue activity the only human tissue with high AOC2- like activity is the retina and expression is associated to the retinal capillaries as shown by immune-histological studies.
• the highest mRNA expression of AOC2 is also found in the mouse retina, however the signals of mRNA and protein expression are found predominantly in the retinal ganglion cell layer.
• the genomic sequence of AOC2 gene contains a stop codon in the exon 1 region, which defines the peptide length to 17% of the mouse and human AOC2 protein giving rise to a non- functional protein (Zhang et al., 2003, Gene 318: 45-53).
• AOC2 physiological function can be reminiscent of the AOC3 homolog which is described as relevant for e.g. neurovascular, retinal inflammation and recruitment of immune cells (Matsuda et al., 2017, Invest Ophthalmol Vis Sci. 58(7): 3254-3261 , Noda et al., 2008, FASEB J.
• AOC3 inhibition a combined inhibition of AOC2 and AOC3 might increase anti-inflammatory potency in man, in particular for the treatment of ocular diseases.
• AOC3 inhibitors are known in the art, for example, the compounds disclosed in WO 2013/163675, WO 2018/027892, WO 2018/148856 and WO 2018/149226.
• the pyridinyl sulfonamide derivatives of the present invention may provide several advantages, such as enhanced potency, improved selectivity, reduced plasma protein binding, improved CYP (cytochrome P450) enzyme profile and high metabolic stability, high chemical stability, improved tissue distribution, e.g. reduced brain exposure, improved side effect profile and/or tolerability and in consequence low toxicity, reduced risk to cause adverse events or undesirable side effects, and enhanced solubility.
• the pyridinyl sulfonamides of the present invention exhibit increased inhibition of human AOC2.
• the pyridinyl sulfonamide derivatives of the present invention exhibit increased selectivity towards AOC1.
• AOC1 expression and enzymatic activity is mainly found in the gut, placenta and kidney.
• the enzyme catalyzes the oxidation of primary amines derived from nutrition and protects the individuum from cardiometabolic effects of histamine, putrescine, tryptamine and cadaverine.
• Inhibition of AOC1 can lead to impaired tolerance to ingested histamine, resulting in increased plasma and tissue histamine-levels which can cause adverse events or undesirable side effects like decreased aterial pressure and compensation by increased heart-rate, tachycardia, headache, flush, urticaria, pruritus, bronchospasm and cardiac arrest (Maintz L. and Novak N. 2007. Am. J. Clin. Nutr. 85: 1185-96).
• the pyridinyl sulfonamide derivatives of the present invention exhibit increased selectivity towards MAO-A.
• This flavoenzyme catalyzes the oxidation of primary amines such as the neurotransmitters dopamine, epinephrine, norepinephrine and serotonine.
• MAO-A is considered to be a key regulator for brain function and there is a link between low activity of MAO and several behavioral and neurological disorders (Shih, J. C. et al. 1999, Annu. Rev. Neurosci. 22: 197- 217; Frazzetto G. et al. 2007, PLoS ONE 5: e486).
• MAO-A plays an important role in the pathogenesis of cardiovascular disorders (Gupta V et al, 2015,
• MAO-A physiologically metabolizes tyramine and consequently protects humans from pathologically high levels of tyramine. Inhibition of MAO-A can lead to a hypertensive crisis if food and beverages high in tyramine are ingested (Sathyanarayana Rao, T. S. 2009, Indian J. of Psychiatry, 51 : 65-66).
• the aim of the present invention is to provide new compounds, in particular new pyridinyl sulfonamide derivatives, which are active with regard to AOC2 and AOC3.
• a further aim of the present invention is to provide new compounds, in particular new pyridinyl sulfonamide derivatives, which have an inhibitory effect on AOC2 and AOC3 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
• a further aim of the present invention is to provide effective dual AOC2 and AOC3 inhibitors, in particular for the treatment of various diseases, for example of cancer, NASH (non-alcoholic steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy and stroke, in particular hemorrhagic stroke.
• various diseases for example of cancer, NASH (non-alcoholic steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy and stroke, in particular hemorrhagic stroke.
• Another aim of the present invention is to provide effective dual AOC2 and AOC3 inhibitors for the treatment of metabolic disorders such as cancer, NASH (non- alcoholic steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy and stroke, in particular hemorrhagic stroke.
• metabolic disorders such as cancer, NASH (non- alcoholic steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy and stroke, in particular hemorrhagic stroke.
• a further aim of the present invention is to provide methods for treating a disease or condition mediated by the inhibition of AOC2 and AOC3 in a patient.
• a further aim of the present invention is to provide a pharmaceutical composition comprising at least one compound according to the invention.
• a further aim of the present invention is to provide a combination of at least one compound according to the invention with one or more additional therapeutic agents.
• a further aim of the present invention is to provide methods for the synthesis of the new compounds, in particular pyridinyl sulfonamide derivatives.
• a further aim of the present invention is to provide starting and/or intermediate compounds suitable in methods for the synthesis of the new compounds.
• the present invention provides a compound of general formula
• ring A is selected from the group A-G1 consisting of:
• the present invention relates to processes for preparing a compound of general formula (I) and to new intermediate compounds in these processes.
• a further aspect of the invention relates to a salt of the compounds of general formula (I) according to this invention, in particular to a pharmaceutically acceptable salt thereof.
• this invention relates to a pharmaceutical composition, comprising one or more compounds of general formula (I) or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more inert carriers and/or diluents.
• this invention relates to a method for treating diseases or conditions which are mediated by inhibiting the activity of AOC3 in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• a method for treating cancer, NASH (non-alcoholic steatohepatitis), pulmonary fibrosis, retinopathy, nephropathy or stroke in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
• this invention relates to a method for treating a disease or condition mediated by the inhibition of AOC3 in a patient that includes the step of administering to the patient in need of such treatment a therapeutically effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more additional therapeutic agents.
• this invention relates to a use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents for the treatment or prevention of diseases or conditions which are mediated by the inhibition of AOC3.
• this invention relates to a pharmaceutical composition which comprises a compound according to general formula (I) or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.
• Ring A is preferably selected from the group A-G1 as defined above.
• ring A is selected from the group A-G2 consisting of
• ring A is selected from the group A-G3 consisting of
• ring A is selected from the group A-G4 consisting of
• ring A is selected from the group A-G5 consisting of
• R 1 -G1 The group R 1 is preferably selected from the group R 1 -G1 as defined above.
• the group R 1 is selected from the group R 1 -G1 a consisting of:
• the second R 1 group of R 1 -G1 , R 1 -G1 a, R 1 -G1 b or R 1 -G1 c is preferably selected from the group consisting of CH3 and CF3.
• Groups R 1 -G2, R 1 -G2a and R 1 -G2b are preferably combined with group A-G2.
• the second R 1 group of R 1 -G2, R 1 -G2a or R 1 -G2b is preferably selected from the group consisting of CH 3 and CF 3 .
• each alkyl group or sub-group is optionally substituted with 1 or more F atoms or with one OH or -0-(Ci -3 -alkyl) group; and wherein m is 0 or 1 ; and wherein each heterocyclyl is selected from the group consisting of azetidinyl, piperidinyl, tetrahydropyranyl and morpholinyl and is optionally substituted with CH 3 group; and wherein multiple R 1 may be identical or different, if n is 2.
• Groups R 1 -G3, R 1 -G3a and R 1 -G3b are preferably combined with group A-G3.
• n is preferably 1 .
• Groups R 1 -G4, R 1 -G4a and R 1 -G4b are preferably combined with group A-G4.
• n is preferably 1 .
• group R 1 is selected from the group R 1 -G5 consisting of:
• Groups R 1 -G5, R 1 -G5a and R 1 -G5b are preferably combined with group A-G5.
• the second R 1 group of R 1 -G5, R 1 -G5a or R 1 -G5b is preferably selected from the group consisting of CH3.
• n is an integer selected from 1 and 2.
• n 1
• n is 2.
• m is an integer selected from 0, 1 and 2.
• m is 0 or 1.
• n 0.
• n 1
• n and the group R 1 are as defined above.
• Preferred compounds of the invention include:
• compound(s) according to this invention denote the compounds of the formula (I) according to the present invention including their tautomers, stereoisomers and mixtures thereof and the salts thereof, in particular the pharmaceutically acceptable salts thereof, and the solvates and hydrates of such compounds, including the solvates and hydrates of such tautomers, stereoisomers and salts thereof.
• the compounds of the invention are always Z-configured in the vinyl fluoride moiety.
• treatment embraces both preventative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment.
• treatment and “treating” comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form.
• Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease.
• compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy.
• treatment and “treating” comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
• this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in particular humans.
• terapéuticaally effective amount means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.
• modulated or “modulating”, or “modulate(s)", as used herein, unless otherwise indicated, refers to the inhibition of AOC3 with one or more compounds of the present invention.
• mediated refers to the (i) treatment, including prevention the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.
• substituted means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound.
• Ci-6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms.
• the last named subgroup is the radical attachment point, for example, the substituent "aryl-Ci-3-alkyl-" means an aryl group which is bound to a Ci-3-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
• An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
• the numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
• the terms“1 -methylpropyl-”,“2,2-dimethylpropyl-“ or“cyclopropylmethyl-“ group represent the following groups:
• the asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
• each X, Y and Z group is optionally substituted with
• each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined.
• R ex denotes H, Ci-3-alkyl, C3-6- cycloalkyl, C 3-6 -cycloalkyl-Ci- 3 -alkyl or Ci- 3 -alkyl-O-, wherein each alkyl group is optionally substituted with one or more L ex .” or the like means that in each of the beforementioned groups which comprise the term alkyl, i.e. in each of the groups Ci- 3 -alkyl, C 3-6 -cycloalkyl-Ci- 3 -alkyl and Ci- 3 -alkyl-O-, the alkyl moiety may be substituted with L ex as defined.
• bicyclic includes spirocyclic.
• a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers etc%) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
• phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
• such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
• Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
• halogen generally denotes fluorine, chlorine, bromine and iodine.
• n is an integer from 1 to n, either alone or in
• Ci-5-alkyl embraces the radicals H 3 C-, H3C-CH2-, H3C-CH2-CH2-, H 3 C-CH(CH 3 )-, H3C-CH2-CH2-CH2-, H 3 C-CH 2 -CH(CH 3 )-, H 3 C-CH(CH 3 )-CH 2 -, H 3 C-C(CH 3 )2-, H3C-CH2-CH2-CH2-, H 3 C-CH2-CH2-CH(CH 3 )-, H 3 C-CH2-CH(CH 3 )-CH2-, H 3 C-CH(CH 3 )-CH2-CH2-, H 3 C- CH 2 -C(CH 3 )2-, H 3 C-C(CH 3 )2-CH 2 -, H 3 C-CH(CH 3 )-CH(CH 3 )- and H3C-CH2- CH
• n is an integer 4 to n, either alone or in
• the cyclic group may be mono-, bi-, tri- or spirocyclic, most preferably monocyclic.
• Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1 ]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc. Many of the terms given above may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.
• the MAO-GloTM Assay (commercially available from PROMEGA, #V1402) provides a sensitive method for the measurement of monoamine oxidase (MAO) activity (Valley, M. P. et al., 2006, Anal. Biochem. 359: 238-246) from a variety of tissues, biofluids or recombinant expressed or purified enzymes.
• MAO monoamine oxidase
• As substrate a derivate of the beetle luciferin ((4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazole-carboxylic acid) is used, which is oxidized at a primary amine moiety. After a spontaneous elimination and a catalyzed esterase reaction, the turnover of luciferin by the luciferase is recorded as a signal of AOC3 activity.
• the compound inhibitors are dissolved in DMSO and adjusted to the respective assay concentration with reaction buffer (50 mM FIEPES, 5 mM KCI, 2 mM CaCh, 1 .4 mM MgCh, 120 mM NaCI, 0.001 % (v/v) Tween 20, 100 mM TCEP, pH 7.4).
• reaction buffer 50 mM FIEPES, 5 mM KCI, 2 mM CaCh, 1 .4 mM MgCh, 120 mM NaCI, 0.001 % (v/v) Tween 20, 100 mM TCEP, pH 7.4
• An aliquot of 3 pl_ of the compound dilution is added to a 384 well plate (Optiplate, PS, flat bottom, white, PERKIN ELMER, #6007290) with a final DMSO concentration of 6.6%.
• Recombinant CHO cells overexpressing the human (1500 cells/well), mouse (1000 cells/well) or rat (500 cells/well) AOC3 enzyme are diluted in reaction buffer and added in a volume of 15 pL to the wells. After incubation for 20 minutes at 37°C, 2 pL of MAO substrate (dissolved in DMSO at 16 mM, adjusted to assay concentration in reaction buffer to a final assay concentration of 20 mM) is added and further incubated for 60 minutes at 37°C. The turnover of the substrate is determined by the addition of 20 mI_ of the detection-mix which was generated by the addition of reconstitution buffer with esterase (PROMEGA, #V1402) to the luciferin detection reagent (PROMEGA, #V1402). After an incubation period of 20 minutes, the luminescent signal is measured with Envision 2104 Multilabel Reader (PERKIN ELMER).
• MAO substrate dissolved in DMSO at 16 mM, adjusted to assay concentration in reaction buffer to a final assay
• Alternative assays for the determination of the AOC3 enzymatic activity could be the extraction of 14 C-labelled benzylamine reaction product or the Amplex Red Monoamine Oxidase reaction (Molecular Probes, Netherlands) as described in Gella et al. (Gella, A. et al., 2013, J. Neural Transm. 120: 1015-1018).
• the compounds of general formula (I) according to the invention for example have IC50 values below 5000 nM, particularly below 1000 nM, preferably below 300 nM, most preferably below 100 nM.
• the Amplex® Red Assay (commercially available from Thermo Fisher Scientific) provides a sensitive method for the detection of H2O2 generated during enzymatic reactions like the amine oxidation catalyzed by AOC2.
• the compound inhibitors are dissolved in DMSO and adjusted to the respective 20x assay concentration with reaction buffer (100 mM sodiumphosphate, 0.05% Pluronic F-127 (#P3000MP Sigma-Aldrich, pH 7.4). An aliquot of 5 pL of the compound dilution is added to a 96 well plate (flat bottom F, black, GREINER bio-one, #655900) in a DMSO concentration of 2%.
• An AOC2 enzyme containing cell homogenate is generated by transient transfection of 6x106 HEK293 cells per flask (T75) with 9 pg pCMV-SPORT6-AOC2 (BC142641 rc, #pCS6(BC142641 )-seq-TCHS1003-GVO-TRI, BioCat) in 750 mI_ of EMEM culture medium (#BE12-61 1 F, Lonza) and 33,75 mI Attractene (#301005, Qiagen). Cells are cultured for 3 days in EMEM culture medium containing 10% FCS (#04-00-1 A, Biological Industries). After washing twice with ice cold PBS, cells are lysed by mechanic homogenation and cleared supernatants are shock frozen in liquid nitrogen and stored at -80°C.
• cell lysates are thawed on ice and 1 :1 diluted with reaction buffer. An Aliquot of 45 mI_ is added to the compound dilution and incubated for 30 min at 37°C. The enzymatic reaction is started with the addition of 50 mI_ of Amplex® Red reaction mix (final assay concentration: 100 mM
• the turnover per time of the substrate is determined directly with a fluorescence reader (Ex 540nm/Em 590nm) like Envision 2104 Multilabel Reader (PERKIN
• the Amplex® Red Assay provides a sensitive method for the detection of H202 generated during enzymatic reactions like the amine oxidation catalyzed by AOC1 .
• the compound inhibitors are dissolved in DMSO and adjusted to the respective assay concentration with reaction buffer (100 mM sodiumphosphate, 0.05% Pluronic F-127 (#P3000MP Sigma-Aldrich), pH 7.4). An aliquot of 3 pL of the compound dilution is added to a 384 well plate (Optiplate, PS, flat bottom F, black, PERKIN ELMER, #6007270) in a DMSO concentration of 6.6%.
• reaction buffer 100 mM sodiumphosphate, 0.05% Pluronic F-127 (#P3000MP Sigma-Aldrich), pH 7.4
• reaction buffer 100 mM sodiumphosphate, 0.05% Pluronic F-127 (#P3000MP Sigma-Aldrich), pH 7.4
• An aliquot of 3 pL of the compound dilution is added to a 384 well plate (Optiplate, PS, flat bottom F, black, PERKIN ELMER, #6007270) in a DMSO concentration of 6.6%
• An AOC1 enzyme aliquot (#8297-AO-010, R&D Systems) is thawed on ice, diluted in reaction buffer and added in a volume of 7 pL to the wells to give a final assay concentration of 1 ng/well. After incubation of inhibitor and enzyme for 30 minutes at 37°C, the enzymatic reaction is started with the addition of 10 pL of Amplex® Red reaction mix (final assay concentration: 100 mM sodiumphosphate, 120 pM Amplex® Red reagent (#A22177 Molecular Probes), 1 .5 U/mL Horseradish Peroxidase
• the MAO-GloTM Assay (commercially available from PROMEGA, #V1402) provides a sensitive method for the measurement of monoamine oxidase (MAO) activity (Valley, M. P. et al., 2006, Anal. Biochem. 359: 238-246) from a variety of tissues, biofluids or recombinant expressed or purified enzymes.
• MAO monoamine oxidase
• As substrate a derivate of the beetle luciferin ((4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazole-carboxylic acid) is used, which is oxidized at a primary amine moiety. After a spontaneous elimination and a catalyzed esterase reaction, the turnover of luciferin by the luciferase is recorded as a signal of MAO-A activity.
• the compound inhibitors are dissolved in DMSO and adjusted to the respective assay concentration with reaction buffer (HEPES 100 mM, Glycerol 5%, pH 7.5). An aliquot of 3 pL of the compound dilution is added to a 384 well plate (Optiplate, PS, flat bottom F, black, PERKIN ELMER, #6007270) in a DMSO concentration of 1.025%.
• reaction buffer HEPES 100 mM, Glycerol 5%, pH 7.5.
• An aliquot of 3 pL of the compound dilution is added to a 384 well plate (Optiplate, PS, flat bottom F, black, PERKIN ELMER, #6007270) in a DMSO concentration of 1.025%.
• a MAO-A enzyme aliquot (M7316, Sigma-Aldrich) is thawed on ice, diluted in reaction buffer to 1.25 mU/pL and added in a volume of 5 pL to the wells. After incubation for 20 minutes at 37°C, 2 pL of MAO substrate (dissolved in DMSO at 16 mM, diluted to
• the turnover of the substrate is determined by the addition of 10 pL of the Detection Reagent mix which was generated by the addition of reconstitution buffer with esterase (PROMEGA, #V1402) to the luciferin detection reagent (PROMEGA, #V1402). After an incubation period of 20 minutes at 37 °C, the luminescent signal is measured with a fluorescence reader, e.g. Envision 2104 Multilabel Reader (PERKIN ELMER).
• a fluorescence reader e.g. Envision 2104 Multilabel Reader (PERKIN ELMER).
• AOC2 enzymatic tissue activity the only human tissue with high AOC2- like activity is the retina and expression is associated to the retinal capillaries as shown by immune-histological studies.
• AOC2 physiological function is reminiscent of the AOC3 homolog which is described as relevant for e.g. neurovascular, retinal inflammation and recruitment of immune cells (Matsuda et al. Invest Ophthalmol Vis Sci. 2017; 58(7):3254-3261 , Noda et al FASEB J. 2008, 4:1094-103).
• Data on pharmacological inhibition or genetic depletion of AOC2 is not available so far. Nonetheless, it is expected that a combined inhibition of AOC2 and AOC3 increases anti-inflammatory potency in man for the treatment of ocular diseases as compared to AOC3 inhibition alone.
• the AOC2 activity was measured, and, suprisingly, it was found out that the pyridinyl sulfonamide compounds of the present invention exhibit an improved inhibition of AOC2 as compared to the closest analogs described in the prior art, e.g. in WO 2013/163675 and WO 2018/027892.
• the compounds according to the present invention are more active inhibitors of AOC2 than the corresponding prior art compounds as described e.g. in WO 2013/163675 and WO 2018/027892; i.e., the replacement of a phenyl or pyrimidinyl moiety by a pyridinyl moiety and the introduction of azetidinyl-, pyrrolidinyl- or piperidinyl-sulfonylamides results in compounds with an improved inhibitory activity towards AOC2, without affecting the activity towards AOC3.
• compound 10 of WO 2013/163675 represents the structurally closest comparison compound as compared to the presently claimed cyclic amines in the same position.
• Compound 10 of WO 2013/163675 contains a dimethylamino-sulfonamide moiety as compared to the cyclic azetidinyl-, pyrrolidinyl- or piperidinyl sulfonamides disclosed in the present invention.
• Compound 10 of WO 2013/163675 contains a phenyl group whereas the compounds disclosed in the present invention contain a pyridinyl group.
• the compounds of the present invention show an improved inhibitory activity against AOC2 as exemplified by Examples 33 and 43 (each only ca. 20-fold less active against AOC2 as compared to AOC3) in the following table.
• reference compounds A and B that structurally differ from examples 33 and 43 of the present invention solely in phenyl versus pyridinyl group can be obtained in analogy to the syntheses described in WO 2013/163675.
• the pyridinyl derivatives of the present invention show an increased inhibitory potency against AOC2.
• Reference compound A is 52-fold (ratio IC50 AOC2 / IC50 AOC3) less active against AOC2 as compared to AOC3, while the pyridinyl analog Example 33 is only 18-fold less active against AOC2.
• Reference compound B is 58-fold less active against AOC2 as compared to AOC3, while the pyridinyl analog Example 43 is only 21 -fold less active against AOC2.
• AOC1 expression and enzymatic activity is mainly found in the gut, placenta and kidney.
• the enzyme catalyzes the oxidation of primary amines derived from nutrition and protects the individuum from cardiometabolic effects of histamine, putrescine, tryptamine and cadaverine.
• Inhibition of AOC1 can lead to impaired tolerance to ingested histamine, resulting in increased plasma and tissue histamine-levels which can cause adverse events or undesirable side effects like decreased aterial pressure and compensation by increased heart-rate, tachycardia, headache, flush, urticaria, pruritus, bronchospasm and cardiac arrest (Maintz L. and Novak N. 2007. Am. J. Clin. Nutr. 85: 1185-96).
• the compounds of the present invention exhibit increased selectivity towards AOC1 as compared to prior art compounds, particularly to the compounds disclosed in WO 2018/027892.
• the Z isomer of example 6 of WO 2018/027892 inhibits AOC1 with an IC50 of 70 nM, whereas the structurally similar example 43 of the present invention has an IC50 of 964 nM, i.e. the compound of the present invention is factor 14 less active on AOC1 that the comparison compound, while the AOC3 potencies of both compounds are comparable.
• MAO-A is a flavoenzyme which catalyzes the oxidation of primary amines such as the neurotransmitters dopamine, epinephrine, norepinephrine and serotonine. Based on this function, MAO-A is considered to be a key regulator for brain function and there is a link between low activity of MAO and several behavioral and neurological disorders (Shih, J. C. et al. 1999, Annu. Rev. Neurosci. 22: 197-217; Frazzetto G. et al. 2007, PLoS ONE 5: e486). Furthermore, MAO-A plays an important role in the pathogenesis of cardiovascular disorders (Gupta V et al, 2015, J.
• MAO-A physiologically metabolizes tyramine and consequently protects humans from pathologically high levels of tyramine. Inhibition of MAO-A can lead to a hypertensive crisis if food and beverages high in tyramine are ingested
• the compounds of the present invention exhibit increased selectivity towards MAO-A as compared to prior art compounds, particularly to the compounds disclosed in WO 2013/163675.
• compound 10 of WO 2013/163675 represents the structurally closest comparison compound as compared to the presently claimed cyclic amines in the same position. While compound 10 of WO 2013/163675 inhibits MAO-A with an IC50 of 7408 nM, the compounds of the present invention typically inhibit MAO-A with an IC50 of greater than 20000 nM, as exemplified by Examples 33 and 43 in the following table.
• the pyridinyl derivatives of the present invention show an improved selectivity against MAO-A. While reference compound A and the pyridinyl analog Example 33 are similarly potent against AOC3, Example 33 shows a much lower inhibitory potency against MAO-A. Reference compounds B and the pyridinyl analog Example 43 are similarly potent against AOC3, however
• Example 43 shows a much lower inhibitory potency against MAO-A. Comparsion of biological data of certain compounds as obtained in the AOC3, AOC2, AOC1 and MAO-A assays as described above:
• the compounds of general formula (I) according to the invention and the corresponding salts thereof are suitable for the treatment, including preventative treatment of all those diseases or conditions which may be affected or which are mediated by the inhibition of AOC3 and AOC2 activity.
• compounds of the present invention show moderate to high in vitro efflux and/or a low intrinsic permeability in an MDCK p-GP assay. Therefore, compounds of the present invention are expected to exhibit a lower free concentration in the brain than in the blood (Liu, H. et al., 2018, Drug Discovery Today 23 (7): 1357-1372).
• the present invention relates to a compound of general formula (I) as a medicament.
• the present invention relates to the use of a compound of general formula (I) for the treatment and/or prevention of diseases or conditions which are mediated by the inhibition of AOC3 in a patient, preferably in a human.
• the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of AOC3 in a mammal that includes the step of administering to a patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
• the compounds of the present invention are particularly suitable for treating inflammatory diseases, such as vascular inflammatory diseases, arthritis, acute and chronic joint inflammation; eczema, such as atopic eczema, psoriasis ulcerative and rheumatoid psoriasis; pain, particularly musculoskeletal or nociceptive pain; inflammatory bowel disease, particularly non-infectious
• inflammatory diseases such as vascular inflammatory diseases, arthritis, acute and chronic joint inflammation
• eczema such as atopic eczema, psoriasis ulcerative and rheumatoid psoriasis
• pain particularly musculoskeletal or nociceptive pain
• inflammatory bowel disease particularly non-infectious
• inflammatory bowel disease multiple sclerosis; scleroderma, pulmonary diseases such as respiratory distress syndrome, asthma, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and idiopathic inflammatory disease; nephropathy, diabetic proteinuria, kidney fibrosis; diabetic retinopathy or diabetic oedema such as macular diabetic oedema; cancer, particularly melanoma and lymphoma; hepatocellular carcinoma, unspecified Colitis, rheumatoid Crohn's disease Colitis; biliary tract diseases, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, liver fibrosis, liver cirrhosis;
• pulmonary diseases such as respiratory distress syndrome, asthma, pulmonary fibrosis
• ulcerative reperfusion injury cerebral ischaemia and transplant rejection.
• the compounds of the present invention are particularly suitable for treating inflammatory diseases, such as vascular inflammatory diseases, arthritis and inflammatory bowel disease, particularly non-infectious inflammatory bowel disease; pulmonary fibrosis and idiopathic pulmonary fibrosis; diabetic retinopathy or diabetic oedema such as macular diabetic oedema; unspecified Colitis, rheumatoid Crohn's disease Colitis; biliary tract diseases, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, liver fibrosis, and liver cirrhosis.
• inflammatory diseases such as vascular inflammatory diseases, arthritis and inflammatory bowel disease, particularly non-infectious inflammatory bowel disease; pulmonary fibrosis and idiopathic pulmonary fibrosis; diabetic retinopathy or diabetic oedema such as
• the dose range of the compounds of general formula (I) applicable per day is usually from 0.001 to 10 mg per kg body weight of the patient, preferably from 0.01 to 8 mg per kg body weight of the patient.
• Each dosage unit may conveniently contain 0.1 to 1000 mg of the active substance, preferably it contains between 0.5 to 500 mg of the active substance.
• the actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a therapeutically effective amount to be delivered based upon the patient’s unique condition.
• Suitable preparations for administering the compounds of formula (I) will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc.
• the content of the pharmaceutically active compound(s) is advantageously in the range from 0.1 to 90 wt.-%, for example from 1 to 70 wt.-% of the composition as a whole.
• Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula (I) with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
• excipients for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants.
• the tablets may also consist of several layers.
• the compounds of the invention may further be combined with one or more, preferably one additional therapeutic agent.
• the additional therapeutic agent is selected from the group of therapeutic agents useful in the treatment of diseases or conditions associated with the metabolic syndrom, diabetes, obesity, cardiovascular diseases, cancer, NASH (non-alcoholic),
• steatohepatitis steatohepatitis
• pulmonary fibrosis pulmonary fibrosis
• retinopathy retinopathy
• nephropathy nephropathy and/or stroke.
• a compound of the invention may be combined with one or more additional therapeutic agents selected from the group consisting of anti-obesity agents
• agents which lower blood glucose include appetite suppressants, agents which lower blood glucose, anti-diabetic agents, agents for treating dyslipidemias, such as lipid lowering agents, anti- hypertensive agents, antiatherosclerotic agents, anti-inflammatory active ingredients, anti-fibrotic agents, agents for the treatment of malignant tumors, antithrombotic agents, anti-angiogenesis agents, agents for the treatment of heart failure and agents for the treatment of complications caused by diabetes or associated with diabetes.
• compounds of the present invention and/or pharmaceutical compositions comprising a compound of the present invention optionally in combination with one or more additional therapeutic agents are administered in conjunction with exercise and/or a diet. Therefore, in another aspect, this invention relates to the use of a compound according to the invention in combination with one or more additional therapeutic agents described hereinbefore and hereinafter for the treatment or prevention of diseases or conditions which may be affected or which are mediated by the inhibition of AOC3, in particular diseases or conditions as described hereinbefore and hereinafter.
• the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of AOC3 in a patient that includes the step of administering to the patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of one or more additional therapeutic agents described in hereinbefore and hereinafter,
• the compound according to the invention and the one or more additional therapeutic agents may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so- called kit-of-parts.
• this invention relates to a pharmaceutical corn- position which comprises a compound according to the invention and one or more additional therapeutic agents described hereinbefore and hereinafter, optionally together with one or more inert carriers and/or diluents.
• Typical methods of preparing the compounds of the invention are described in the experimental section.
• the potent inhibitory effect of the compounds of the invention can be determined by in vitro enzyme assays as described in the experimental section.
• the compounds of the present invention may also be made by methods known in the art including those described below and including variations within the skill of the art.
• the vinylfluorid E/Z- isomers of compounds of the general formula I may be separated by preparative HPLC or column chromatography on silica gel which affords compounds of the general formula I in isomerically pure form.
• the synthetic routes presented may rely on the use of protecting groups.
• reactive groups present such as hydroxy, carbonyl, carboxy, amino, alkylamino or imino, may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
• Suitable protecting groups for the respective functionalities and their removal are well known to the one skilled in the art and are described in the literature of organic synthesis.
• the compounds of general formula I may be resolved into their enantiomers and/or diastereomers as mentioned before.
• the compounds of general formula I which occur as racemates may be separated by methods known per se into their optical antipodes and diastereomeric mixtures of compounds of general formula I may be resolved into their diastereomers by taking advantage of their different physico-chemical properties using methods known per se, e.g. chromatography and/or fractional crystallization; if the compounds obtained thereafter are racemates, they may be resolved into the enantiomers as mentioned above.
• racemates are preferably resolved by column chromatography on chiral phases or by crystallization from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as esters or amides with the racemic compound.
• Salts may be formed with enantiomerically pure acids for basic compounds and with enantiomerically pure bases for acidic compounds.
• Diastereomeric derivatives are formed with enantiomerically pure auxiliary
• the compounds of formula I may be converted into salts, particularly for pharmaceutical use into the pharmaceutically acceptable salts.
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• reaction progress is monitored by thin layer chromatography (TLC) or HPLC- MS.
• TLC thin layer chromatography
• HPLC- MS HPLC- MS.
• Reaction progress may be monitored by conventional methods such as thin layer chromatography (TLC) or high pressure liquid chromatography-mass spec (HPLC-MS).
• TLC thin layer chromatography
• HPLC-MS high pressure liquid chromatography-mass spec
• Step 1 Amide-coupling: (S)-Pyrrolidine-1 ,3-dicarboxyl ic acid 1 -tert-butyl ester (0.5 g, 2.32 mmol) was dissolved in THF (5.00 ml_) and TEA (2.61 ml_; 18.58 mmol) and a solution of dimethylamine in THF (2 M; 2.32 ml_; 4.65 mmol) was added. To the reaction mixture was added a solution of 1 -propanephosphonic acid cyclic anhydride (50% in THF; 2.71 ml_; 4.65 mmol) at RT. The reaction mixture was stirred at RT and diluted with 4 N aq. sodium hydroxide. The aq.
• Step 2 BOC deprotection: The crude material of step 1 was diluted with MeOH (20 mL) and treated with 4 N HCI in 1 ,4-dioxane (5 mL; 20.00 mmol) at RT. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo to provide intermediate I.2.
• Step 1 Amide-coupling: (R)-Pyrrolidine-1 ,3-dicarboxylic acid 1 -tert-butyl ester (800 mg, 3.61 mmol) was dissolved in THF (5.00 ml_) and TEA (4.05 ml_; 28.84 mmol) and a solution of methylamine in THF (2 M; 3.61 ml_; 7.21 mmol) was added. To the reaction mixture was added a solution of 1 -propanephosphonic acid cyclic anhydride (50% in THF; 4.21 ml_; 7.21 mmol) at RT. The reaction mixture was stirred at RT for 1 h and diluted with 4 N aq. sodium hydroxide (20 ml_). The aq. phase was extracted with MTBE (2 x 20 ml_) and the pooled organic phases were washed with brine, dried, filtered and concentrated in vacuo.
• Step 2 - BOC deprotection The crude material of step 1 was diluted with EtOAc (20 nriL) and treated with 4 N HCI in 1 ,4-dioxane (2 ml_; 8.00 mmol) at RT. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo to provide intermediate I.5.
• Step 1 Amide-coupling: (S)-Pyrrolidine-1 ,3-dicarboxylic acid 1 -terf-buytl ester (500 mg, 2.32 mmol) was dissolved in THF (4.50 ml_) and TEA (2.61 ml_; 18.58 mmol) and a solution of morpholine (220 mg; 2.56 mmol) in THF (0.5 ml_) was added. To the reaction mixture was added a solution of 1 -propanephosphonic acid cyclic anhydride (50% in THF; 2.71 ml_; 4.65 mmol) at RT. The reaction mixture was stirred at RT for 3 h and diluted with 4 N aq.
• Step 2 - BOC deprotection The crude material of step 1 was diluted with MeOH (20 mL) and treated with 4 N HCI in 1 ,4-dioxane (5 mL; 20.00 mmol) at RT. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo and co-evaporated with toluene (50 mL) to provide intermediate I.7.
• Step 1 Amide-coupling: 4-Methyl-piperidine-1 ,4-dicarboxyl ic acid mono-te/t-butyl ester (500 mg, 1 .99 mmol) was dissolved in THF (5 mL) and TEA (2.24 mL; 15.95 mmol) and a solution of ethylamine in THF (2 M; 1 .99 mL; 3.99 mmol) was added. To the reaction mixture was added a solution of 1 -propanephosphonic acid cyclic anhydride (50% in THF; 2.33 mL; 3.99 mmol) at RT. The reaction mixture was stirred at RT for 1 h and diluted with 4 N aq. sodium hydroxide (20 mL). The aq. phase was extracted with MTBE (2 x 20 mL) and the pooled organic phases were washed with brine (20 mL), dried, filtered and concentrated in vacuo.
• Step 2 - BOC deprotection The crude material of step 1 was diluted with EtOAc (20 mL) and treated with 4 N HCI in 1 ,4-dioxane (1 mL; 4.00 mmol) at RT. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo to provide intermediate I.9.
• Step 1 Amide-coupling: trans-3-Aza-bicyclo[3.1 0]hexane-3,6-dicarboxylic acid 3-tert- butyl ester (1 ,00 g, 4.40 mmol) was dissolved in THF (5 mL) and TEA (4.94 mL; 35.20 mmol) and a solution of methylamine in THF (2 M; 4.40 mL; 8.80 mmol) was added. To the reaction mixture was added a solution of 1 -propanephosphonic acid cyclic anhydride (50% in THF; 5.14 mL; 8.80 mmol) at RT. The reaction mixture was stirred at RT for 45 min and diluted with 4 N aq. sodium hydroxide (25 mL). The aq. phase was extracted with MTBE (2 x 25 mL) and the pooled organic phases were dried with Na2S0 4 , filtered and concentrated in vacuo.
• Step 2 - BOC deprotection The crude material of step 1 was diluted with EtOAc (20 mL) and MeOH (20 mL) and treated with 4 N HCI in 1 ,4-dioxane (5 mL;
• Stepl - Amide-coupling (R)-Pyrrolidine-1 ,3-dicarboxylic acid 1 -terf-butyl ester (800 mg; 3.61 mmol) was diluted with DCM (8 mL) and N-methylmorpholine (0.45 mL; 3.97 mmol) was added. The reaction mixture was cooled to 0°C and IBCF (0.5 mL; 3.79 mmoL) was added. The reaction mixture was stirred at 0°C for 5 min, warmed to RT and stirred for 1 h at RT. After addition of aq. NH 4 OH (32%; 0.67 mL; 5.41 mmol) the reaction mixture was stirred at RT for 80 min.
• Step2 - BOC deprotection The crude material of step 1 was dissolved in DCM (5 ml_), TFA (0.83 ml_; 10,81 mmol) was added and the reaction mixture was stirred at RT for 1 h. To the reaction mixture was added TFA (0.83 ml_; 10.81 mmol) and it was stirred at RT overnight. The reaction mixture was concentrated in vacuo to provide intermediate 1.15.
• Piperidine-4-carboxylic acid methyl ester (1.15 g; 6.39 mmol) was suspended in DCM (40 mL) and a solution of TEA (3.56 mL; 25.56 mmol) and 6-fluoropyridine-3-sulfonyl chloride (1.25 g; 6.39 mmol) in DCM (10 mL) was added. The reaction mixture was stirred at RT for 45 min. The reaction mixture was diluted with DCM (50 mL) and extracted with water (2 x 40 ml_). The organic phase was dried with Na 2 S0 4 and the solvent was evaporated. The crude material was suspended in MTBE and the solid was filtered to give intermediate 111.1.
• Example 1 1- ⁇ 1-[6-((Z)-2-Aminomethyl-3-fluoro-allyloxy)-pyridine-3-sulfonyl]- piperidine-4-yl ⁇ -3-methyl-imidazolidin-2-one trifluoroacetate
• intermediate VI.4 To a solution of intermediate VI.4 (30 mg; 0.06 mmol) in DMF (2 ml_) was added TEA (69 mI_; 0.49 mmol) and HATU (23 mg; 0.06 mmol) and the reaction mixture was stirred at RT for 10 min. Ammonium carbonate (30 mg; 0.31 mmol) was added to the reaction mixture and it was stirred at RT overnight. The reaction mixture was purified by RP-HPLC (ACN/ water + NH 4 OH) to provide intermediate VII.4.
• Example 48 1-[6-((Z)-2-Aminomethyl-3-fluoro-allyloxy)-pyridine-3-sulfonyl]-4- methyl-piperidine-4-carboxylic acid (tetrahydropyran-4-yl)-amide

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pulmonology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=64082993

Family Applications (1)

Country Status (5)

Cited By (4)

Families Citing this family (2)

Citations (3)

Family Cites Families (53)

• 2019
  • 2019-10-24 US US17/285,916 patent/US12213970B2/en active Active
  • 2019-10-24 CN CN201980071186.0A patent/CN112955214B/zh active Active
  • 2019-10-24 EP EP19794969.6A patent/EP3873599B1/en active Active
  • 2019-10-24 WO PCT/EP2019/078991 patent/WO2020089025A1/en not_active Ceased
  • 2019-10-24 JP JP2021523214A patent/JP7425793B2/ja active Active

Patent Citations (4)

Non-Patent Citations (53)

Also Published As

Similar Documents

Legal Events